Remdesivir
Intravenous remdesivir 200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions.
Placebo
Placebo matched remdesivir, loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
2:1 ratio. Concomitant use of lopinavir–ritonavir, interferons, and corticosteroids permitted.
COVID-19 severe or critically
Hospitalized patients with laboratory-confirmed SARS-CoV-2 infection, within 12 days of symptoms onset , oxygen saturation of 94% or less on ambient air or a ratio SaO2/FiO2 of 300 mm Hg or less, and radiologically confirmed pneumonia.
Double-blind.
10 hospitals in Hubei, China.
The six-point scale was as follows: death=6; hospital admission for extracorporeal membrane oxygenation or mechanical ventilation=5; hospital admission for noninvasive ventilation or high-flow oxygen therapy=4; hospital admission for oxygen therapy (but not requiring high-flow or non-invasive ventilation)=3; hospital admission but not requiring oxygen therapy=2; and discharged or having reached discharge criteria (defined as clinical recovery—ie, normalisation of pyrexia, respiratory rate <24 breaths per minute, saturation of peripheral oxygen >94% on room air, and relief of cough, all maintained for at least 72 h)=1.
Study prematurely discontinued because of the control of the outbreak in Wuhan after March 12.One patient in the placebo group who withdrew after randomisation was not included in the ITT population.